The National Medical Insurance Administration issued a document in response to promoting the inclusion of biological drugs in centralized procurement

On August 17, the National Medical Insurance Bureau issued a letter on the response to Proposal No.

The original text is as follows:

National Medical Security Administration on the Fourth Meeting of the 13th National Committee of the Chinese People's Political Consultative Conference

Letter of Reply to Proposal No.

Medical Insurance Letter (2021) No.

Member Bian Huijie:

Your proposal on promoting the healthy development of the biopharmaceutical industry and exploring a suitable biopharmaceutical procurement mechanism has been received.

In accordance with the decisions and deployments of the Party Central Committee and the State Council, starting from 2018, the National Medical Insurance Administration, in conjunction with relevant departments, has actively promoted the reform of centralized drug procurement, and has successfully carried out five batches of 218 drug centralized procurement

1.

Your suggestions for promoting the linkage of the tripartite policies of medicine, medical insurance, and medical care have been reflected in the promotion of centralized procurement reform.

2.

We attach great importance to your suggestion to explore a procurement mechanism suitable for biological agents

Thank you for your attention to medical security work, and hope to support our work as always

National Medical Security Administration

July 30, 2021